

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

BSE Limited 1 st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u> Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan	National Stock Exchange of India Limited Exchange Plaza, 5 th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u> Kind Attn.: Famroze Pochara Asst. Vice President
Date: October 5, 2017	
Re.: Press Release	

Dear Sir / Madam,

We enclose herewith a copy of press release dated October 5, 2017 titled "Zydus receives final approval from the USFDA for Fesoterodine Fumarate Extended-Release Tablets".

The contents of the press release give full details.


Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**

for

UPEN H. SHAH
COMPANY SECRETARY



Encl.: As above

Zydus receives final approval from the USFDA for Fesoterodine Fumarate Extended-Release Tablets

Ahmedabad, 05 October 2017

Zydus Cadila has received the final approval from the USFDA to market Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad. Fesoterodine is used to treat an overactive bladder with symptoms of urinary frequency, urgency, and incontinence.

The sales of Fesoterodine Fumarate Extended-Release Tablets are estimated at \$195.5 million. *Source: IMS Health, IMS National Sales Perspective Audit, MAT August 2017, extracted October 2017.*

The group now has more than 160 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
